Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Idiopathic Pulmonary Fibrosis Treatment Market, By Drug Class
7.1. Idiopathic Pulmonary Fibrosis Treatment Market, By Drug Class, 2020-2028
7.1.1. MAPK Inhibitors
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. Tyrosine Inhibitors
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Autotaxin Inhibitors
7.1.3.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Idiopathic Pulmonary Fibrosis Treatment Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.2. Europe
8.2.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.3. APAC
8.3.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.4. MEA
8.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.5. Latin America
8.5.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, By Drug Class (2016-2028)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, By Drug Class (2016-2028)
Chapter 9. Company Profiles
9.1. F. Hoffman La-Roche Ltd
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Boehringer Ingelheim International GmbH
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Prometic Life Sciences Inc.
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. FibroGen, Inc.
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Bristol-Myers Squibb Company
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. MediciNova, Inc.
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Galapagos
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. Merck & Co., Inc.
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. Novartis AG
9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
Glossary of Terms